Assessment of study quality
The trials were considered to be valid if they met the inclusion criteria and if they supplied sufficient data for further analysis. The authors do not state how the papers were assessed for validity, or how many of the reviewers performed the validity assessment.
Data extraction
Data concerning all outcomes of interest were extracted from all eligible studies and entered into spreadsheets. The authors do not state how many of the reviewers performed the data extraction, or whether any cross-checking process was undertaken.
Methods of synthesis
How were the studies combined? Success rate differences were displayed as forest plots. When no heterogeneity across trials was demonstrated, the rate differences were pooled using a fixed-effect model.
How were differences between studies investigated?
Differences between the studies were investigated using the Q statistic and 95% confidence intervals were calculated. Sources of heterogeneity were discussed in the text of the review.
Results of the review
The review included 95 RCTs, a number of which compared more than one intervention. A total of 5,663 patients were recruited by the studies.
Eighteen RCTs investigated CSA (n=2,350). Of these, 13 (n=1,688) concerned the induction of remission in patients with active disease and 5 (n=662) concerned the maintenance of remission. Thirty-three RCTs (n=2,419) compared the use of oral retinoids with either each other, another intervention or placebo. Fifty RCTs (n=2,876) compared the use of phototherapy and photochemotherapy with either other phototherapy or photochemotherapy regimes, another intervention or placebo. Four studies (n=258) examined the use of fumarates, and there was one study each of hydroxyurea (n=166) and sulphasalazine (n=188); all 6 of these studies enrolled only patients with active disease.
No RCTs were found that investigated the use of methotrexate or azathioprine in the treatment of psoriasis.
There was considerable heterogeneity within each intervention group. The sources of heterogeneity included the drug dose, duration of treatment, baseline severity of disease, success criterion and mix of patients (by psoriasis subgroup). In trials of phototherapy, an additional source of heterogeneity was the mix of patients according to the skin type. Drug formulation and patient compliance may also have played a role.
The evidence suggested that CSA was usually effective in inducing the remission of psoriasis when used in the dose range of 2.5 to 5.0 mg/kg per day. Doses above 5.0 mg/kg per day were associated with increased side-effects, which precluded any dose-related gains in efficacy. Maintenance treatment required a dose of 3.0 to 3.5 mg/kg per day, and although relapses were more likely if the drug was given intermittently (as opposed to continuously), intermittent treatment appeared to be safer.
The evidence suggested that retinoids were moderately effective as monotherapy at doses of 75 mg/day or 1 mg/kg per day. Acitretin was as effective as etretinate, which was less effective than CSA. The evidence supported the use of combined treatments of a retinoid and PUVA. This combination was more effective than retinoid therapy alone and had the advantage of lowering the cumulative UVA dose.
There was no evidence from RCTs to support the use of methotrexate. PUVA using oral psoralen (8-methoxypsoralen, 0.6 to 1.0 mg/kg) was found to be effective in clearing psoriasis, and PUVA using topical psoralen ('bath PUVA') was equally effective. UVA alone, however, did not clear psoriasis.
The conclusion drawn and the consequent recommendations appear to follow well from the data presented. The implications for health professionals and the recommendations for future research were comprehensive, and appear to have been written with regard to the limitations of the review as well as the information it found.
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Implications of the review for practice and research
Practice: The authors state that, although the availability of RCTs has dictated that the report dealt exclusively with systemic treatments and phototherapies, it is important to be aware that patients with severe psoriasis are frequently treated by means of in-patient or day-treatment centre management (e.g. topical dithranol combined with UVB phototherapy), for which there are no published RCTs. Thus, the recommendation of systemic therapies should not preclude traditional in-patient or day-treatment centre management.
Research: The authors state that high-quality RCTs are needed in a number of areas, but suggest that two critical steps should be taken before further trials are started. First, outcome measures of relevance to both clinicians and patients should be developed to assess therapeutic response in psoriasis. Second, a definition of 'severe psoriasis' should be established. If possible, such a definition should be all-encompassing and holistic in its outlook, incorporating not only the clinical severity of psoriasis but psychosocial disability and historical disease behaviour. The authors state that the following RCTs of treatments for severe psoriasis could be justified: CSA versus methotrexate; systemic therapy or phototherapy versus in-patient and/or day-treatment centre management; acitretin versus methotrexate in a long-term study; fumarates versus methotrexate in both short-and long-term studies; narrowband UVB versus PUVA in both short-and long-term studies; hydroxyurea versus placebo; azathioprine versus placebo; and sulphasalazine versus placebo.
There is justification for performing economic evaluations, including more formal cost-effectiveness and cost-utility studies of the various treatment options, particularly in comparison with in-patient and day-treatment centre management. All future trials should include an economic evaluation and be of sufficient duration for the impact on patients to be determined.
